Ignite Creation Date:
2025-12-24 @ 9:09 PM
Ignite Modification Date:
2026-01-03 @ 6:48 PM
Study NCT ID:
NCT03853304
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-04-01
First Post:
2019-02-22
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Quadruple Fortified Salt Trial in India
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000740', 'term': 'Anemia'}, {'id': 'D005494', 'term': 'Folic Acid Deficiency'}, {'id': 'D014806', 'term': 'Vitamin B 12 Deficiency'}], 'ancestors': [{'id': 'D006402', 'term': 'Hematologic Diseases'}, {'id': 'D006425', 'term': 'Hemic and Lymphatic Diseases'}, {'id': 'D014804', 'term': 'Vitamin B Deficiency'}, {'id': 'D001361', 'term': 'Avitaminosis'}, {'id': 'D003677', 'term': 'Deficiency Diseases'}, {'id': 'D044342', 'term': 'Malnutrition'}, {'id': 'D009748', 'term': 'Nutrition Disorders'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D005492', 'term': 'Folic Acid'}, {'id': 'D014805', 'term': 'Vitamin B 12'}], 'ancestors': [{'id': 'D011622', 'term': 'Pterins'}, {'id': 'D011621', 'term': 'Pteridines'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D045728', 'term': 'Corrinoids'}, {'id': 'D045725', 'term': 'Tetrapyrroles'}, {'id': 'D011758', 'term': 'Pyrroles'}, {'id': 'D001393', 'term': 'Azoles'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006576', 'term': 'Heterocyclic Compounds, 4 or More Rings'}, {'id': 'D047028', 'term': 'Macrocyclic Compounds'}, {'id': 'D011083', 'term': 'Polycyclic Compounds'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR'], 'maskingDescription': 'All salt formulations will be similar in taste, appearance, and texture. Salt will be packaged in bags labeled with color codes known only to the salt manufacturers and a statistician unaffiliated with the study. A statistician unaffiliated with this study will generate a random number sequence for intervention allocation. Blinding will be maintained until initial data analysis is completed.'}, 'primaryPurpose': 'PREVENTION', 'interventionModel': 'FACTORIAL', 'interventionModelDescription': 'After confirming eligibility and informed consent/assent, women will be randomly assigned to one of the 4 intervention arms, using a 2 X 2 factorial design:\n\n1. Quadruple-fortified salt (QFS; i.e., iron, iodine, folic acid, and vitamin B12)\n2. DFS + folic acid\n3. DFS + vitamin B12; and\n4. Double-fortified salt (DFS; i.e., iron and iodine)'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 1000}}, 'statusModule': {'overallStatus': 'ACTIVE_NOT_RECRUITING', 'startDateStruct': {'date': '2023-10-01', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-03', 'completionDateStruct': {'date': '2024-12', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2024-03-29', 'studyFirstSubmitDate': '2019-02-22', 'studyFirstSubmitQcDate': '2019-02-22', 'lastUpdatePostDateStruct': {'date': '2024-04-01', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2019-02-25', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-12', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Concentrations of erythrocyte folate and serum folate', 'timeFrame': 'Endpoint (12 months)', 'description': 'Erythrocyte folate and serum folate concentrations, nmol/L'}, {'measure': 'Concentrations of hemoglobin', 'timeFrame': 'Endpoint (12 months)', 'description': 'Hemoglobin concentrations, g/dL'}, {'measure': 'Concentrations of vitamin B12', 'timeFrame': 'Endpoint (12 months)', 'description': 'Vitamin B12 concentrations, pmol/L'}], 'secondaryOutcomes': [{'measure': 'Folate deficiency and insufficiency', 'timeFrame': 'Endpoint (12 months)', 'description': 'Erythrocyte (RBC) folate \\<305.0 nmol/L; \\<748.0 nmol/L'}, {'measure': 'Anemia', 'timeFrame': 'Endpoint (12 months)', 'description': 'Hemoglobin \\<12.0 g/dL'}, {'measure': 'Vitamin B12 deficiency and insufficiency', 'timeFrame': 'Endpoint (12 months)', 'description': 'Total vitamin B12 \\<148.0 pmol/L; \\<221.0 pmol/L'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Anemia', 'Folate Deficiency', 'Vitamin B 12 Deficiency']}, 'referencesModule': {'references': [{'pmid': '34027296', 'type': 'BACKGROUND', 'citation': 'Finkelstein JL, Fothergill A, Johnson CB, Guetterman HM, Bose B, Jabbar S, Zhang M, Pfeiffer CM, Qi YP, Rose CE, Williams JL, Bonam W, Crider KS. Anemia and Vitamin B-12 and Folate Status in Women of Reproductive Age in Southern India: Estimating Population-Based Risk of Neural Tube Defects. Curr Dev Nutr. 2021 Apr 26;5(5):nzab069. doi: 10.1093/cdn/nzab069. eCollection 2021 May.'}, {'pmid': '33122315', 'type': 'BACKGROUND', 'citation': 'Finkelstein JL, Fothergill A, Johnson CB, Guetterman HM, Bose B, Jabbar S, Zhang M, Pfeiffer CM, Qi YP, Rose CE, Krisher JT, Ruth CJ, Mehta R, Williams JL, Bonam W, Crider KS. Periconceptional surveillance for prevention of anaemia and birth defects in Southern India: protocol for a biomarker survey in women of reproductive age. BMJ Open. 2020 Oct 29;10(10):e038305. doi: 10.1136/bmjopen-2020-038305.'}, {'pmid': '37181934', 'type': 'BACKGROUND', 'citation': 'Finkelstein JL, Guetterman HM, Fothergill A, Johnson CB, Qi YP, Jabbar S, Zhang M, Pfeiffer CM, Rose CE, Yeung LF, Williams JL, Krisher JT, Ruth C, Roy Choudhury D, Venkatramanan S, Haas JD, Kuriyan R, Mehta S, Bonam W, Crider KS. A Randomized Trial of Quadruple-Fortified Salt for Anemia and Birth Defects Prevention in Southern India: Protocol Design and Methods. Curr Dev Nutr. 2023 Feb 21;7(3):100052. doi: 10.1016/j.cdnut.2023.100052. eCollection 2023 Mar.'}, {'pmid': '35623855', 'type': 'BACKGROUND', 'citation': 'Finkelstein JL, Fothergill A, Guetterman HM, Johnson CB, Bose B, Qi YP, Rose CE, Williams JL, Mehta S, Kuriyan R, Bonam W, Crider KS. Iron status and inflammation in women of reproductive age: A population-based biomarker survey and clinical study. Clin Nutr ESPEN. 2022 Jun;49:483-494. doi: 10.1016/j.clnesp.2022.02.123. Epub 2022 Mar 5.'}, {'pmid': '39490799', 'type': 'DERIVED', 'citation': 'Guetterman HM, Rajagopalan K, Fox AM, Johnson CB, Fothergill A, George N, Krisher JT, Haas JD, Mehta S, Williams JL, Crider KS, Finkelstein JL. A Randomized Crossover Trial of Acceptability of Quadruple-Fortified Salt in Women and their Households in Southern India. J Nutr. 2025 Jan;155(1):322-337. doi: 10.1016/j.tjnut.2024.10.037. Epub 2024 Oct 26.'}]}, 'descriptionModule': {'briefSummary': 'Women of reproductive age are at an increased risk of anemia and micronutrient deficiencies. Evidence supports the role of periconceptional nutrition in the development of neural tube defects and other pregnancy complications. Vitamin B12 deficiency is a risk factor for neural tube defects and may modify folate biomarkers that predict neural tube defect risk at the population level. There is an interest in mandatory fortification with vitamin B12 and folic acid for anemia and birth defect prevention. However, there are limited population-representative data needed to inform policy and guidelines. This randomized trial will be conducted to evaluate the efficacy of quadruple-fortified salt (QFS; iron, iodine, folic acid, vitamin B12) in 1,000 women and their households in Southern India.', 'detailedDescription': 'Women of reproductive age are at increased risk for anemia and micronutrient deficiencies, due in part to social structures and increased nutritional requirements across the conceptional period. Anemia is an important public health problem and has been associated with risk of adverse pregnancy outcomes, including maternal and infant mortality, preterm delivery, and low birth weight. Iron deficiency is the leading cause of anemia worldwide, accounting for 20% to half of the anemia cases. Deficiencies in folate and/or vitamin B12 also result in megaloblastic anemia, and inadequate periconceptional folate and vitamin B12 status have been linked to pregnancy complications, including birth defects.\n\nNeural tube defects are among the most common and debilitating birth defects in the United States and globally. Neural tube defects are structural birth defects that arise when the neural folds fail to fuse entirely during early embryogenesis. It is estimated that there are over 260,000 cases of neural tube defects per year globally, ranging from 1 to 80 per 10,000 births, with higher prevalence in low- and middle-income countries. India has one of the highest burdens of neural tube defects in the world, accounting for over one-third of all neural tube defects globally.\n\nThe links between maternal folate status and neural tube defect risk in offspring have been well established. In randomized trials, periconceptional folic acid supplementation reduced the risk of neural tube defects by approximately 70%. Fortification of staple foods with folic acid is one of the most efficacious and cost-effective public health interventions and has been linked to decreased neural tube defects in national folic acid fortification programs. Fortification interventions to date have primarily targeted wheat (and maize) flour, which are not primary staples in some settings with the highest burden of neural tube defects, such as Southern India and China.\n\nThere is increasing interest in fortification strategies targeting additional staple foods and micronutrient deficiencies in at-risk populations. Emerging evidence suggests that vitamin B12 deficiency is associated with an increased risk of neural tube defects independent of folate status and may modify red blood cell folate concentrations which are used to predict risk of neural tube defects at the population level. In Southern India, the setting of this randomized trial, rice is the primary staple and folic acid fortification is not currently mandatory. Findings from a recently completed population-based pre-intervention biomarker survey in this setting demonstrated a substantial burden of anemia and micronutrient deficiencies of iron, vitamin B12, and folate in women of reproductive age. Together, these findings underscore the potential benefits of developing additional fortification strategies to deliver folic acid and other micronutrients for prevention of anemia and neural tube defects.\n\nSalt fortification is a promising strategy to prevent multiple micronutrient deficiencies, as it is widely consumed, affordable, and has existing production and distribution systems. In India, salt is one of the most widely consumed and fortifiable foods, and double-fortified salt (i.e., with iron and iodine) is included in the national fortification guidelines and social safety net programs in India for prevention of anemia and iron deficiency. Randomized trials demonstrated that double-fortified salt significantly improved serum ferritin or iron deficiency in women of reproductive age and school children. Findings from meta-analyses suggest that double-fortified salt improves hemoglobin concentrations and decreases risk of anemia; however, findings from double-fortified salt trials in India for anemia have been heterogeneous. For example, in a randomized trial of double-fortified salt among Indian female tea pickers by Haas et al., double-fortified salt improved hemoglobin, serum ferritin, total body iron, and soluble transferrin receptor levels, compared with iodized salt without iron, after adjusting for the respective baseline bio- markers. However, the prevalence of anemia (53%) as well as vitamin B12 (37%) and folate (86%) deficiencies remained high at endpoint. These findings highlight the need to develop additional interventions to target other nutritional causes of anemia and multiple micronutrient deficiencies (i.e., vitamin B12 and folate).\n\nRecent technological advances informed the development of a quadruple-fortified salt - i.e., iodine, iron, folic acid, and vitamin B12, which can be adjusted to the level of salt intake in populations. Quadruple-fortified salt has undergone preliminary testing for organoleptic properties and consumer acceptability and is ready for use in randomized efficacy trials in human populations.\n\nThe objective of this randomized trial is to evaluate the efficacy of quadruple-fortified salt-i.e., iodine, iron, folic acid, and vitamin B12-on improving 1) hemoglobin, 2) red blood cell folate and serum folate, and 3) vitamin B12 concentrations, among women of reproductive age in Southern India.'}, 'eligibilityModule': {'sex': 'FEMALE', 'stdAges': ['ADULT'], 'maximumAge': '49 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Women between 18 and 49 years of age\n* Healthy\n* Not pregnant or lactating\n* Plan to reside in the catchment area of our periconceptional surveillance program for at least two years\n\nExclusion Criteria:\n\n* Severe anemia (Hemoglobin \\<8.0 g/dL)\n* Reported diagnosis of HIV, malaria infection, or active tuberculosis disease\n* Malabsorption disorders (i.e., medical conditions that may affect vitamin B12 absorption or metabolism)\n* Stage 2 hypertension (SBP≥140 mm Hg or DBP≥90 mm Hg)\n* Glycated hemoglobin (HbA1c) ≥6.5%\n* Other serious pre-existing medical conditions (e.g., defined as the need for regular medication use), active infections, or acute illnesses\n* Previous pregnancy affected by a neural tube defect (i.e., who have had a fetus diagnosed as affected by a neural tube defect or have given birth to a baby with a neural tube defect) (will be referred to OB/GYN for standard of care, including folic acid supplementation, and excluded)\n* Planning to become pregnant (or planning to have a child) in the next 12 months (will be referred to OB/GYN for standard of care, including folic acid supplementation, and be excluded)\n* Daily micronutrient supplements (i.e., tablets, capsules, dispersible tablets; ≥4 times in the past week)\n* Intramuscular or intravenous interventions containing medications or micronutrients (e.g., iron, vitamin B12, folic acid) in the past 3 months'}, 'identificationModule': {'nctId': 'NCT03853304', 'acronym': 'QFS', 'briefTitle': 'Quadruple Fortified Salt Trial in India', 'organization': {'class': 'OTHER', 'fullName': 'Cornell University'}, 'officialTitle': 'A Randomized Trial of Quadruple Fortified Salt for Anemia and Birth Defects Prevention in Southern India', 'orgStudyIdInfo': {'id': '86613'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Quadruple-Fortified Salt (QFS)', 'description': 'Salt fortified with iron, iodine, folic acid, and vitamin B12', 'interventionNames': ['Other: + Folic acid', 'Other: + Vitamin B12', 'Other: DFS']}, {'type': 'EXPERIMENTAL', 'label': 'DFS + Folic acid', 'description': 'Salt fortified with iron, iodine, and folic acid', 'interventionNames': ['Other: + Folic acid', 'Other: DFS']}, {'type': 'EXPERIMENTAL', 'label': 'DFS + Vitamin B12', 'description': 'Salt fortified with iron, iodine, and vitamin B12', 'interventionNames': ['Other: + Vitamin B12', 'Other: DFS']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Double-fortified salt (DFS)', 'description': 'Salt fortified with iron and iodine', 'interventionNames': ['Other: DFS']}], 'interventions': [{'name': '+ Folic acid', 'type': 'OTHER', 'description': 'Salt fortified with folic acid', 'armGroupLabels': ['DFS + Folic acid', 'Quadruple-Fortified Salt (QFS)']}, {'name': '+ Vitamin B12', 'type': 'OTHER', 'description': 'Salt fortified with vitamin B12', 'armGroupLabels': ['DFS + Vitamin B12', 'Quadruple-Fortified Salt (QFS)']}, {'name': 'DFS', 'type': 'OTHER', 'description': 'Salt fortified with iron and iodine', 'armGroupLabels': ['DFS + Folic acid', 'DFS + Vitamin B12', 'Double-fortified salt (DFS)', 'Quadruple-Fortified Salt (QFS)']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Madanapalle', 'state': 'Andhra Pradesh', 'country': 'India', 'facility': 'Arogyavaram Medical Centre', 'geoPoint': {'lat': 13.5503, 'lon': 78.50288}}], 'overallOfficials': [{'name': 'Julia L Finkelstein, MPH SM ScD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Cornell University'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Cornell University', 'class': 'OTHER'}, 'collaborators': [{'name': 'Centers for Disease Control and Prevention', 'class': 'FED'}, {'name': 'Arogyavaram Medical Centre', 'class': 'OTHER'}], 'responsibleParty': {'type': 'SPONSOR'}}}}